Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide in Chinese Patients With Relapsing Multiple Sclerosis
ChiCTR2600120683Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teriflunomide in multiple sclerosis (MS), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Incidence of adverse reactions at 24 months and Annual relapse rate at 24 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ChiCTR2600120683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120683.